Iovance Biotherapeutics (formerly Lion Biotechnologies) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes. The Company's lead product candidate is an autologous, ready-to-infuse cell therapy that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. In addition to metastatic melanoma, Lion's TIL technology is potentially applicable to all solid tumors, including ovarian, colorectal, head and neck, and other cancers.